Section of Hematology & Immunology
Mission Statement
Our focus is to test newly developed drugs in the immunologic and coagulation field.
We try to combine in vitro, ex vivo and in vivo trials to obtain an integrated insight into pathophysiologic processes.
Current Projects
- First in man trials including basket trials with chemokines, cytokines, antibodies, aptamers and biosimilarity trials with biologicals
- Drug trials in human LPS infusion or lung instillation model to measure pharmacodynamics of novel compounds under standardized conditions of inflammation.
- Phase I-III patient trials, to monitor immunmodulation and coagulation in various diseases including stroke.
- Target on vessels, platelets and coagulation: Platelet hyperfunction in myocardial infarction, thrombotic microangiopathies, critically ill, extracorporeal circulations (hemodialysis, cardiopulmonary bypass, extracorporeal membrane oxygenation, left ventricular assist devices)
- Development of recombinant human diamine oxidase against mast cell activation disorders and anaphylaxis
Key Publications
1. Gludovacz E, Schuetzenberger K, Resch M, Tillmann K, Petroczi K, Schosserer M, Vondra S, Vakal S, Klanert G, Pollheimer J, Salminen TA, Jilma B, Borth N, Boehm T: Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmceutical. Elife. 2021 Sep 3;10:e68542. doi: 10.7554/eLife.68542
2. Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S: Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8; 384(14):1323-1334. doi:10.1056/NEJMoa2027760.
3. Boehm T, Reiter B, Ristl R, Petroczi K, Sperr W, Stimpfl T, Valent P, Jilma B: Massive release of the histamine-degrading enzyme diamine oxidase during severe anaphylasis in mastocytosis patients. Allergy 2019 Mar;74(3):583-593. doi: 10.1111/all.13663
4. Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B: Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin. Blood 2019 Feb 28;133(9):893-901. doi: 10.1182/blood-2018-06-856930
5. Peyvandi F, Sully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni W, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichs H, Duby C, Tersago D: TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombozytopenic Purpura. New Entl J Med. 2016 Feb11;374(6):511-522. doi: 10.1056/NEJMoa1505533
For information please contact our Section Head:
Bernd Jilma, MD
E-Mail: bernd.jilma@meduniwien.ac.at
Quick Links
Featured
